MedPage Today on MSN3d
Prior Auth Requirements Did Not Reduce Costs in Total Hip Arthroplasty
Prior authorization (PA) requirements for patients undergoing primary total hip arthroplasty did not reduce costs, but did ...
Clinical Pain Advisor17h
In-Hospital Mortality After Total Hip Arthroplasty: Which Sex Faces a Higher Risk?
There were no sex-related differences in-hospital mortality after elective primary total hip arthroplasty for osteoarthritis.
MedPage Today on MSN10h
Studies Hint at Potential Negative Effects of GLP-1 Drugs in Orthopedic Patients
SAN DIEGO -- Two retrospective studies hinted at potential negative effects of GLP-1 receptor agonists for patients requiring ...
Mexborough Elective Orthopaedic Centre sets new regional record with five arthroplasty surgeries in a single day
The Mexborough Elective Orthopaedic Centre of Excellence (MEOC) has reached an impressive milestone this month, completing ...
Clinical Pain Advisor18h
AAOS: Stopping GLP-1 RAs 14 Days Before Surgery Can Minimize Complications
Stopping GLP-1 RA treatment 14 days before total joint arthroplasty can minimize risks for complications, according to study findings.
Healio2d
Optimal timing for cessation of GLP-1 receptor agonists prior to TJA may be 14 days
Stopping GLP-1 receptor agonists 14 days prior to total hip or knee arthroplasty may reduce several key risk factors ...
New report confirms Smith+Nephew’s OXINIUM™ Technology is the best performing bearing surface at 20 years for total hip arthroplasty
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, is pleased to announce that the latest annual report ...
Healio14h
Weight loss with GLP-1 receptor agonists before THA may increase mortality risk
Results presented here showed patients who had significant weight loss prior to total hip arthroplasty with use of a GLP-1 receptor agonist experienced a decreased risk for complications but an ...
Yahoo Finance4d
Shoulder Innovations secures $40m to advance arthroplasty systems
Shoulder Innovations has secured $40m in a Series E equity financing round, to mainly progress the commercialisation of its InSet Total Shoulder and Reverse Shoulder Arthroplasty Systems.